|
1
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Azzoli CG, Baker S Jr, Temin S, Pao W,
Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, et
al American Society of Clinical Oncology: American Society of
Clinical Oncology Clinical Practice Guideline update on
chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol.
27:6251–6266. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang X, Zhao J, Zhu W, Gou H, Cao D, Yang
Y, Huang Y and Yi C: Synergistic effect of subtoxic-dose cisplatin
and TRAIL to mediate apoptosis by down-regulating decoy receptor 2
and up-regulating caspase-8, caspase-9 and Bax expression on
NCI-H460 and A549 Cells. Iran J Basic Med Sci. 16:710–718.
2013.PubMed/NCBI
|
|
5
|
Stegehuis JH, de Wilt LH, de Vries EG,
Groen HJ, de Jong S and Kruyt FA: TRAIL receptor targeting
therapies for non-small cell lung cancer: Current status and
perspectives. Drug Resist Updat. 13:2–15. 2010. View Article : Google Scholar
|
|
6
|
Luster TA, Carrell JA, McCormick K, Sun D
and Humphreys R: Mapatumumab and lexatumumab induce apoptosis in
TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when
treated in combination with bortezomib. Mol Cancer Ther. 8:292–302.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jung Y-H, Heo J, Lee YJ, Kwon TK and Kim
Y-H: Quercetin enhances TRAIL-induced apoptosis in prostate cancer
cells via increased protein stability of death receptor 5. Life
Sci. 86:351–357. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schaefer U, Voloshanenko O, Willen D and
Walczak H: TRAIL: A multifunctional cytokine. Front Biosci.
12:3813–3824. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dillon CP, Oberst A, Weinlich R, Janke LJ,
Kang TB, Ben-Moshe T, Mak TW, Wallach D and Green DR: Survival
function of the FADD-CASPASE-8-cFLIP(L) complex. Cell Reports.
1:401–407. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Maldonado ME, Bousserouel S, Gossé F,
Lobstein A and Raul F: Implication of NF-κB and p53 in the
expression of TRAIL-death receptors and apoptosis by apple
procyanidins in human metastatic SW620 cells. Biomedica.
30:577–586. 2010. View Article : Google Scholar
|
|
11
|
Haag C, Stadel D, Zhou S, Bachem MG,
Möller P, Debatin KM and Fulda S: Identification of c-FLIPL and
c-FLIPS as critical regulators of death receptor-induced apoptosis
in pancreatic cancer cells. Gut. 60:225–237. 2010. View Article : Google Scholar
|
|
12
|
Falschlehner C, Emmerich CH, Gerlach B and
Walczak H: TRAIL signalling: Decisions between life and death. Int
J Biochem Cell Biol. 39:1462–1475. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Earel JK Jr, VanOosten RL and Griffith TS:
Histone deacetylase inhibitors modulate the sensitivity of tumor
necrosis factor-related apoptosis-inducing ligand-resistant bladder
tumor cells. Cancer Res. 66:499–507. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Papageorgiou A, Lashinger L, Millikan R,
Grossman HB, Benedict W, Dinney CP and McConkey DJ: Role of tumor
necrosis factor-related apoptosis-inducing ligand in
interferon-induced apoptosis in human bladder cancer cells. Cancer
Res. 64:8973–8979. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee KH, Lim SW, Kim HG, Kim DY, Ryu SY,
Joo JK, Kim JC and Lee JH: Lack of death receptor 4 (DR4)
expression through gene promoter methylation in gastric carcinoma.
Langenbecks Arch Surg. 394:661–670. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bae SI, Cheriyath V, Jacobs BS, Reu FJ and
Borden EC: Reversal of methylation silencing of Apo2L/TRAIL
receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and
SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL.
Oncogene. 27:490–498. 2008. View Article : Google Scholar
|
|
17
|
Suzuki M, Shigematsu H, Shivapurkar N,
Reddy J, Miyajima K, Takahashi T, Gazdar AF and Frenkel EP:
Methylation of apoptosis related genes in the pathogenesis and
prognosis of prostate cancer. Cancer Lett. 242:222–230. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Horak P, Pils D, Haller G, Pribill I,
Roessler M, Tomek S, Horvat R, Zeillinger R, Zielinski C and
Krainer M: Contribution of epigenetic silencing of tumor necrosis
factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL
resistance and ovarian cancer. Mol Cancer Res. 3:335–343. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Eramo A, Pallini R, Lotti F, Sette G,
Patti M, Bartucci M, Ricci-Vitiani L, Signore M, Stassi G, Larocca
LM, et al: Inhibition of DNA methylation sensitizes glioblastoma
for tumor necrosis factor-related apoptosis-inducing
ligand-mediated destruction. Cancer Res. 65:11469–11477. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Keating GM: Azacitidine: A review of its
use in higher-risk myelodysplastic syndromes/acute myeloid
leukaemia. Drugs. 69:2501–2518. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cataldo VD, Cortes J and Quintás-Cardama
A: Azacitidine for the treatment of myelodysplastic syndrome.
Expert Rev Anticancer Ther. 9:875–884. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kaminskas E, Farrell A, Abraham S, Baird
A, Hsieh LS, Lee SL, Leighton JK, Patel H, Rahman A, Sridhara R, et
al FDA: Approval summary: Azacitidine for treatment of
myelodysplastic syndrome subtypes. Clin Cancer Res. 11:3604–3608.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vaitkienė P, Skiriutė D, Skauminas K and
Tamašauskas A: Associations between TFPI-2 methylation and poor
prognosis in glioblastomas. Medicina (Kaunas). 48:345–349.
2012.
|
|
24
|
Dong SW, Ma L, Xu N, Yan HQ, Liu HY, Li YW
and Zhang P: Research on the reactivation of Syk expression caused
by the inhibition of DNA promoter methylation in the lung cancer.
Neoplasma. 58:89–95. 2011. View Article : Google Scholar
|
|
25
|
Lin CT, Lai HC, Lee HY, Lin WH, Chang CC,
Chu TY, Lin YW, Lee KD and Yu MH: Valproic acid resensitizes
cisplatin-resistant ovarian cancer cells. Cancer Sci. 99:1218–1226.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Avraham A, Cho SS, Uhlmann R, Polak ML,
Sandbank J, Karni T, Pappo I, Halperin R, Vaknin Z, Sella A, et al:
Tissue specific DNA methylation in normal human breast epithelium
and in breast cancer. PLoS One. 9:e918052014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yan H and Sun J: Methylation status of
WWOX gene promoter CpG islands in epithelial ovarian cancer and its
clinical significance. Biomed Rep. 1:375–378. 2013.
|
|
28
|
Baylin SB and Jones PA: A decade of
exploring the cancer epigenome - biological and translational
implications. Nat Rev Cancer. 11:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tan S, Sun C, Wei X, Li Y and Wu Y, Yan Z,
Feng F, Wang J and Wu Y: Quantitative assessment of lung cancer
associated with genes methylation in the peripheral blood. Exp Lung
Res. 39:182–190. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kupčinskaitė-Noreikienė R, Skiecevičienė
J, Jonaitis L, Ugenskienė R, Kupčinskas J, Markelis R, Baltrėnas V,
Sakavičius L, Semakina I, Grižas S, et al: CpG island methylation
of the MLH1, MGMT, DAPK, and CASP8 genes in cancerous and adjacent
noncancerous stomach tissues. Medicina (Kaunas). 49:361–366.
2013.
|
|
31
|
Balgkouranidou I, Liloglou T and Lianidou
ES: Lung cancer epigenetics: Emerging biomarkers. Biomarkers Med.
7:49–58. 2013. View Article : Google Scholar
|
|
32
|
Xie F-W, Peng Y-H, Wang W-W, Chen X, Chen
X, Li J, Yu ZY and Ouyang XN: Influence of UGT1A1 gene methylation
level in colorectal cancer cells on the sensitivity of the
chemotherapy drug CPT-11. Biomed Pharmacother. 68:825–831. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xie F-W, Peng Y-H, Chen X, Chen X, Li J,
Yu ZY, Wang WW and Ouyang XN: Regulation and expression of aberrant
methylation on irinotecan metabolic genes CES2, UGT1A1 and GUSB in
the in-vitro cultured colorectal cancer cells. Biomed Pharmacother.
68:31–37. 2014. View Article : Google Scholar : PubMed/NCBI
|
